[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anastomotic-leakage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anastomotic-leakage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,41,76,112,136,162,183,214,237,267,291,314],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100640416","the-value-of-early-postoperative-colonoscopy-in-the-early-diagnosis-of-anastomotic-leakage-after-surgery-for-low-colorectal-cancer-100640416",false,"NCT07588386","The Value of Early Postoperative Colonoscopy in The Early Diagnosis of Anastomotic Leakage After Surgery for Low Colorectal Cancer","The Value of Early Postoperative Colonoscopy in The Early Diagnosis of Anastomotic Leakage After Surgery for Low Colorectal Cancer:A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years old.\n2. Pathologically diagnosed as colorectal adenocarcinoma.\n3. The distance between the lower edge of the tumor and the anal verge is ≤15cm.\n4. Accept laparoscopic or open radical resection and complete primary colorectal or colosal anastomosis.\n5. Voluntarily participate and sign the written informed consent.\n\nExclusion Criteria:\n\n1. Distant metastasis was confirmed by emergency operation, palliative operation or intraoperative metastasis (M1).\n2. Unsatisfactory anastomosis or poor blood circulation were found during the operation, and reinforcement suture or preventive colostomy were performed during the operation.\n3. There are serious contraindications for enteroscopy (such as acute myocardial infarction, severe cardiopulmonary insufficiency, blood coagulation dysfunction, etc.).\n4. Pregnant or lactating women.\n5. Previous history of colorectal surgery (except endoscopic polypectomy).\n6. Unable to understand or cooperate with the research process.","ALL","18 Years","80 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether early postoperative colonoscopy is valuable in the early diagnosis of anastomotic leakage after surgery for low colorectal cancer.The main questions it aims to answer are:\n\n1. Will the median diagnosis time of AL in the intervention group (early colonoscopy group) be significantly shorter than that in the control group?\n2. Can targeted treatment (such as endoscopic vacuum therapy (EVT)) be initiated earlier in the early colonoscopy group, thereby reducing the incidence of AL and the rate of unplanned re-laparotomy?\n\nResearchers will compare the median diagnosis time of AL in the intervention group (early colonoscopy group) with the control group to observe whether early postoperative colonoscopy can detect anastomotic leakage earlier.\n\nParticipants will:\n\nExperimental group (early colonoscopy group):\n\n1. Colonoscopy will be performed on the 5th to 8th day after surgery (the surgeon will decide the specific date within this time window based on the patient's recovery).\n2. Carry out adequate intestinal preparation before the examination (the specific plan is formulated according to the hospital's routine, which may involve antegrade or retrograde enema, etc., and needs to be recorded and standardized).\n\nControl group (routine observation group):\n\n1. Receive standard postoperative management, including monitoring vital signs, abdominal signs, drainage fluid properties, etc.\n2. Only when clinical symptoms suspected of anastomotic leakage occur (such as persistent fever, worsening abdominal pain, turbid drainage fluid or stool samples), CT scan, gastrointestinal angiography or diagnostic colonoscopy should be performed according to clinical indications.",[27],"Anastomotic Leakage","RECRUITING","2026-06-20",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":21},"2026-06-21",{"date":36,"type":21},"2027-06-30",{"name":38,"class":39},"Nanchong Central Hospital","OTHER_GOV",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":40},"100643351","vacstent-use-for-the-treatment-of-anastomotic-leakage-following-colorectal-surgery-100643351","NCT07631702","VACStent Use for the Treatment of Anastomotic Leakage Following coloREctal Surgery","VACStent Use for the Treatment of Anastomotic Leakage Following Colorectal Surgery: a Multicenter Prospective Efficacy Study","VACURE","Inclusion Criteria:\n\n* AL in the distal sigmoid, upper or mid rectum following a colorectal resection\n* ≥ 18 years old.\n* Signed a written informed consent\n\nExclusion Criteria:\n\n* Anastomosis that is not endoscopically accessible.\n* Contra-indications for VacStent GI therapy: (a) Significant tissue ischemia in the area of the wound cavity, larger than the length of the VacStent GI Colon; (b) Anastomotic defect located \\\u003C4 cm from the dentate line. This is considered a relative contraindication, as very distal placement may cause patient discomfort although not necessarily; (c) Severe coagulopathy; (d) Ileus that does not allow for endoscopic examination.\n* Anastomotic fistula to surrounding organs (vagina, bladder, small bowel)",{"count":50,"type":21},40,[24],"Introduction: Anastomotic leakage (AL) is the most severe complication following colorectal surgery and is associated with significant morbidity and mortality. VacStent therapy is a promising therapeutic approach, combining endoscopic vacuum therapy with mechanical stability of a stent and thereby allowing continued fecal passage. It may enhance anastomotic healing and reduce the need for a diverting ostomy or additional surgical procedures. VACStent Use for the treatment of anastomotic leakage following coloREctal surgery (VACURE) study aims to assess the efficacy and safety of VacStent therapy for colorectal AL.\n\nMethods and analysis: VACURE is a prospective, multicenter efficacy study conducted at ten Dutch hospitals. Forty patients will be included over 18 months. All patients (≥18 years) with AL of the distal sigmoid, upper or mid rectum following colorectal resection will be considered for treatment with the VacStent GI Colon device. Trained endoscopists will perform stent placement, exchanges, and removal. Patients will remain hospitalized and those without diverting ostomy will receive osmotic laxatives and a fiber-free diet during treatment. Anastomotic healing will be confirmed endoscopically and radiologically posttreatment. The primary endpoint is the primary endpoint is the rate of participants that achieve complete anastomotic healing without the need for further interventions (confirmed by radiologic and endoscopic assessment). Secondary endpoints include safety, percentage of functioning anastomoses at 1 year post-treatment, 1-year stoma-free survival, diverting ostomy omission, healing time, number of stents, complications, reinterventions, length of hospitalization, pain scores, functional and quality of life outcomes up to 1 year posttreatment, patient experiences, and cost-effectiveness.",[54,55,56,57,58,27,59],"Colorectal Surgery","Anastomotic Leak Rectum","Endoscopy, Digestive System","Vacuum Therapy","Stents","Minimal Invasive",[61,62,63,64],"Postoperative Complications","Anastomotic Leak","Vacuum stent","Endoscopic vacuum therapy","NOT_YET_RECRUITING","2026-06-03",{"date":68,"type":32},"2026-06-08",{"date":70,"type":21},"2026-07-01",{"date":72,"type":21},"2028-10-01",{"name":74,"class":75},"Amsterdam UMC, location VUmc","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100637489","somatostatin-plus-clear-liquid-diet-versus-diverting-stoma-in-patients-with-rectal-cancer-undergoing-ultra-low-anterior-resection-100637489","NCT07605611","Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection","A Multicenter, Randomized Clinical Study of Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Low and Mid Rectal Cancer Undergoing Ultra-Low Anterior Resection","SC-Stoma","Inclusion Criteria:\n\n1. Adults aged 18 to 75 years\n2. Patients with stage I to III rectal malignancy who are scheduled to undergo low anterior resection at a participating gastrointestinal surgery center\n3. The lower edge of the tumor is 8 cm or less from the dentate line, or 10 cm or less from the anal verge, based on preoperative colonoscopy, imaging, or digital rectal examination\n4. The planned anastomosis is expected to be 2 cm or less from the dentate line, or 4 cm or less from the anal verge\n5. Patients have two or more risk factors for anastomotic leakage as assessed by the study team\n6. American Society of Anesthesiologists physical status classification is grade 3 or lower\n7. Body mass index is less than 30 kg\u002Fm²\n8. The patient, or the patient's legally authorized representative, is willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Has another colorectal malignant tumor at the same time\n2. The final anastomosis after surgery is more than 2 cm from the dentate line, or more than 4 cm from the anal verge\n3. Has metastatic disease before surgery\n4. Is pregnant\n5. Has a mental illness or addictive disorder that would prevent participation in the clinical trial\n6. Requires emergency surgery\n7. Has inflammatory bowel disease\n8. Is allergic to somatostatin or is unable to tolerate somatostatin\n9. For participants assigned to the no-stoma group, the surgeon decides that a stoma is required\n10. Has received neoadjuvant drug therapy less than 2 weeks before surgery, or radiotherapy less than 8 weeks before surgery\n11. Has any other condition that makes it impossible to follow the study protocol","75 Years",{"count":86,"type":21},72,[24],"The goal of this clinical trial is to learn if somatostatin plus a clear liquid diet can help prevent severe leakage after rectal cancer surgery in adults with low or mid rectal cancer who are scheduled to have ultra-low anterior resection. These patients have a higher risk of leakage where the bowel is joined together after surgery.\n\nThe main questions it aims to answer are:\n\nDoes somatostatin plus a clear liquid diet prevent severe leakage within 1 month after surgery about as well as a prophylactic diverting stoma?\n\nWhat medical problems, bowel function problems, recovery outcomes, and quality of life outcomes do participants have after surgery and during follow-up?\n\nResearchers will compare somatostatin plus a clear liquid diet without a diverting stoma to prophylactic diverting stoma to see if the somatostatin plus clear liquid diet regimen can provide similar protection against severe leakage while reducing the need for stoma creation.\n\nParticipants will:\n\nHave rectal cancer surgery with the bowel joined very close to the anus\n\nBe randomly assigned to receive either somatostatin plus a clear liquid diet for 7 days after surgery without a diverting stoma, or a prophylactic diverting stoma\n\nHave follow-up assessments of leakage, postoperative complications, bowel function, recovery quality, and quality of life\n\nComplete follow-up visits or assessments for up to 3 years after surgery",[90,27],"Rectal Cancer",[92,93,94,95,96,97,98,99,100,101],"Rectal cancer","Ultra-low anterior resection","Anastomotic leakage","Severe anastomotic leakage","Diverting stoma","Prophylactic stoma","Somatostatin","Clear liquid diet","Bowel function","Quality of life","2026-05-22",{"date":104,"type":32},"2026-05-26",{"date":106,"type":32},"2025-11-17",{"date":108,"type":21},"2030-06-30",{"name":110,"class":75},"Tongji Hospital",3,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":40},"100582617","efficacy-and-safety-of-colorectal-anastomotic-leak-testing-100582617","NCT06865638","Efficacy and Safety of Colorectal Anastomotic Leak Testing","A Comparative Study of Clinical Outcomes Between Leak Testing and No Leak Testing for Anastomosis in Colorectal Cancer Surgery: a Multicenter, Stratified Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients diagnosed with colorectal cancer by pathology and scheduled for surgical treatment who meet the surgical indications.\n2. Aged between 18 and 85 years.\n3. American Society of Anesthesiologists (ASA) physical status classification is I - III.\n4. The patient or his\u002Fher legal representative can understand and sign the informed consent form and is willing to cooperate throughout the study process.\n\nExclusion Criteria:\n\n1. Patients with preoperatively diagnosed anastomotic leak or other severe abdominal infections.\n2. Patients with severe cardiovascular and cerebrovascular diseases (such as recent myocardial infarction, unstable angina pectoris, severe heart failure, acute cerebral infarction, etc.) who cannot tolerate surgery and related tests.\n3. Patients with severely impaired liver and kidney function (liver function Child - Pugh classification C or above, creatinine clearance rate \\\u003C 30 ml\u002Fmin).\n4. Patients with coagulation disorders (such as platelet count \\\u003C 50×10⁹\u002FL, international normalized ratio (INR) \\> 1.5, etc.) that cannot be corrected or are receiving anticoagulant therapy that cannot be adjusted.\n5. Patients with a history of abdominal radiotherapy or multiple abdominal surgeries and severe abdominal adhesions that may affect the operation and detection procedures.\n6. Patients with other malignant tumors who are receiving active anti-tumor treatment such as radiotherapy and chemotherapy.\n7. Patients with mental illness or cognitive impairment who cannot cooperate with the study process and follow-up.","85 Years",{"count":121,"type":21},264,[24],"To evaluate the effectiveness of the gastroscopy, air, and methylene blue (GAM) leak testing in reducing the incidence of postoperative anastomotic complications, especially anastomotic leakage, in patients with colorectal cancer. The primary outcomes included is the incidence of anastomotic complications (mainly anastomotic leak) within 30 days after surgery",[125,126,54,127,27],"Colorectal Cancer","Leakage Testing","Complications","2026-03-29",{"date":130,"type":32},"2026-03-31",{"date":132,"type":32},"2024-12-22",{"date":134,"type":21},"2029-04-01",{"name":38,"class":39},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":40},"100551814","stapler-reinforcement-patches-compared-to-standard-staplers-in-gastrojejunostomy-100551814","NCT06464978","Stapler Reinforcement Patches Compared to Standard Staplers in Gastrojejunostomy","The Impact of Stapler Reinforcement Patches Compared to Standard Staplers on Postoperative Complications in Gastrojejunostomy: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 85 years.\n* Pathologically diagnosed with gastric cancer and suitable for distal gastrectomy or subtotal gastrectomy.\n* ECOG performance status of 0 or 1.\n* ASA (American Society of Anesthesiologists) classification of I-III.\n* Voluntary signed informed consent from the participant or their legal representative.\n\nExclusion Criteria:\n\n* Evidence of potential distant metastasis found preoperatively.\n* History of other malignancies diagnosed within the past 5 years, or any malignancy treated with chemotherapy or radiotherapy.\n* Significant contraindications for surgery (e.g., severe liver or kidney dysfunction).\n* Participation in any other clinical trial within the last 6 months.\n* Participants or their legal representatives unwilling to sign the informed consent or comply with the study protocol.",{"count":144,"type":21},382,[24],"This is a multi-center, prospective, randomized controlled study aimed at compareing the impact of stapler reinforcement patches versus standard staplers on postoperative complications in gastrojejunostomy.",[148,149,27,61],"Gastric Cancer","Gastrostomy",[151,152,153,154,155],"Stapler Reinforcement Patch","Gastrojejunostomy","Randomized Controlled Trial","Surgical Outcomes","Complication Prevention",{"date":130,"type":32},{"date":158,"type":32},"2024-05-30",{"date":160,"type":21},"2028-12-31",{"name":38,"class":39},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":40},"100608994","pre-emptive-endoscopic-vacuum-therapy-reduces-the-incidence-of-anastomotic-leakage-after-colorectal-cancer-surgery-100608994","NCT07208786","Pre-emptive Endoscopic Vacuum Therapy Reduces the Incidence of Anastomotic Leakage After Colorectal Cancer Surgery","Randomized Clinical Trial on Pre-emptive Endoscopic Vacuum Therapy Versus Conventional Management for the Prevention of Anastomotic Leakage After Colorectal Cancer Surgery","Inclusion Criteria:\n\n1. Pathologically diagnosed with colorectal cancer, planned for radical surgery (right hemicolectomy, left hemicolectomy, or anterior resection of the rectum, etc.).\n2. Age 18-85 years, American Society of Anesthesiologists (ASA) classification I-III.\n3. Anastomosis to be performed in a single stage (meeting anastomotic criteria).\n4. Patient or legal guardian is able to understand and sign the informed consent form and comply with follow-up.\n\nExclusion Criteria:\n\n1. Preexisting anastomotic leakage or severe intra-abdominal infection before surgery.\n2. Complicated by severe cardiovascular or cerebrovascular diseases (e.g., acute myocardial infarction, acute phase of cerebral infarction).\n3. Severe liver or kidney dysfunction (liver function Child-Pugh class C, creatinine clearance \\\u003C30 ml\u002Fmin).\n4. Coagulation disorders (platelets \\\u003C50×10⁹\u002FL, INR \\>1.5) or receiving anticoagulant therapy that cannot be adjusted.\n5. History of abdominal radiotherapy or multiple abdominal surgeries leading to severe intra-abdominal adhesions.\n6. Complicated by other malignant tumors and currently undergoing radiotherapy or chemotherapy.\n7. Psychiatric illness or cognitive impairment preventing compliance with the study.",{"count":170,"type":21},110,[24],"Evaluate the safety and efficacy of postoperative Pre-emptive EVT (PEVT) in reducing the incidence of anastomotic leaks within 30 days after surgery in patients with colorectal cancer. Compare the differences between the PEVT group and the control group in terms of operation time, length of hospital stay, and total medical costs. Analyze the incidence of other postoperative complications in the two groups, such as wound infection, abdominal abscess, and intestinal obstruction. Assess the impact of PEVT on postoperative recovery indicators, including time to first flatus, time to first defecation, and time to ambulation. Observe the occurrence of PEVT-related adverse events, such as device displacement, bleeding, and infection.",[125,54,127,27,174],"Endoscopic Vacuum Therapy","2026-03-28",{"date":177,"type":32},"2026-04-02",{"date":179,"type":32},"2025-09-22",{"date":181,"type":21},"2026-12-30",{"name":38,"class":39},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":213},"100625032","single-stapled-technique-for-colorectal-anastomosis-100625032","NCT07417358","Single-Stapled Technique for Colorectal Anastomosis","Single-Stapled Technique for Colorectal Anastomosis After Left-Sided Colectomy, Sigmoid Resection or Partial Mesorectal Excision: A Multicentre Prospective Observational Cohort Study","SST","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Planned (elective) left-sided colorectal resection with creation of a colorectal anastomosis, including: Left hemicolectomy, and\u002For Sigmoid resection, and\u002For Partial mesorectal excision (PME).\n* Benign or malignant indication.\n* Prospective cohort: Ability to provide written informed consent.\n* Retrospective cohort: Eligible patients operated during 2023-2025 at participating centers, identified through medical record review, meeting the same surgical inclusion criteria.\n\nExclusion Criteria:\n\n* Total mesorectal excision (TME) (e.g., low rectal cancer surgery requiring TME).\n* Non-left-sided colorectal resections (e.g., right-sided colectomy) or procedures outside the study-defined operations.\n* Surgery not involving a colorectal anastomosis (e.g., end colostomy\u002FHartmann's procedure without anastomosis).\n* Emergency\u002Furgent colorectal resection (non-elective surgery).\n* Prospective cohort: Inability to provide informed consent.",{"count":192,"type":21},500,"OBSERVATIONAL","The goal of this observational multicenter study is to evaluate the safety and feasibility of a single-stapled technique (SST) for colorectal anastomosis and to explore whether this technique is associated with a reduced rate of anastomotic leakage compared with the conventional double-stapled technique (DST).\n\nThe study includes adult patients undergoing planned left-sided colorectal resection with colorectal anastomosis, including sigmoid resection, left hemicolectomy, or partial mesorectal excision (PME), for benign or malignant disease.\n\nThe main questions it aims to answer are:\n\nWhat is the rate of anastomotic leakage within 90 days after surgery in patients operated with the single-stapled technique?\n\nIs the single-stapled technique feasible and safe across different surgical approaches (open, laparoscopic, and robot-assisted surgery) in a multicenter setting?\n\nFurthermore, outcomes after single-stapled anastomosis will be compared with a retrospective cohort of patients operated with the conventional double-stapled technique to explore potential differences in anastomotic leakage rates and postoperative complications.\n\nParticipants will receive standard surgical care as determined by the treating surgical team. Patients included in the prospective part of the study will undergo colorectal anastomosis using the single-stapled technique as part of routine clinical practice. Data on perioperative variables, postoperative complications (including anastomotic leakage graded according to international consensus definitions), and follow-up outcomes will be collected prospectively using an electronic case report form (eCRF). A retrospective cohort from the same participating centers will be identified through medical record review using identical inclusion criteria.\n\nThe results of this study are intended to provide robust multicenter data on the safety and clinical outcomes of the single-stapled technique and to serve as the basis for planning a future randomized controlled multicenter trial.",[125,196,27,197],"Colorectal Anastomosis","Diverticular Disease of Left Side of Colon",[199,200,94,201,202,203],"Single-stapled anastomosis","Colorectal anastomosis","Colorectal surgery","Left-sided colon resection","Partial mesorectal excision","2026-02-10",{"date":206,"type":32},"2026-02-18",{"date":208,"type":32},"2026-01-07",{"date":210,"type":21},"2029-06-30",{"name":212,"class":75},"Umeå University",5,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":220,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":40},"100607523","study-on-the-correlation-between-serum-and-fecal-sialic-acid-levels-and-tumor-characteristics-as-well-as-postoperative-anastomotic-leakage-in-patients-with-colorectal-tumors-100607523","NCT07189663","Study on the Correlation Between Serum and Fecal Sialic Acid Levels and Tumor Characteristics as Well as Postoperative Anastomotic Leakage in Patients With Colorectal Tumors","Inclusion Criteria: For the retrospective Part : Age between 18 and 80 years; Patients who underwent radical resection of colorectal cancer in our hospital from January 2010 to December 2020; Preoperative serum sialic acid level was measured (a routine test item in liver function biochemical tests in our hospital from 2010 to 2020); Complete postoperative pathological data.\n\n* For the prospective Section:Age between 18 and 80 years; Patients who underwent radical resection of colorectal cancer in our hospital from August 2025 to August 2026; Voluntarily sign the informed consent form for fecal sample collection.\n\nExclusion Criteria:\n\n* Emergency surgery, palliative surgery, or concurrent other malignant tumors; Preoperative neoadjuvant chemoradiotherapy (may affect SA levels and microbiota); Recent infection: history of severe infection within 3 months before surgery.",{"count":221,"type":21},1468,"This is a Single-center bidirectional cohort study combined with prospective sample analysis conducted by the Department of General Surgery at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital).\n\nThe purpose of this study was to retrospectively collect the preoperative serum sialic acid content and postoperative pathological data of colorectal cancer patients in our hospital's medical order system (including tumor size and stage, etc.) and anastomotic leakage, and analyze the correlation between serum sialic acid content and pathological characteristics of tumor and the correlation between anastomotic leakage; and further collect the feces of colorectal cancer patients in our hospital for 16S microbiome sequencing, and detect their sialic acid content, and observe the relationship between fecal sialic acid content and tumor size and stage; Intestinal flora composition and postoperative anastomotic leakage correlation, provide a new theoretical basis for the prevention and treatment of postoperative anastomotic malhealing.",[224,27],"Colorectal Neoplasia",[226,227,228],"colorectal neoplasia","anastomotic leakage","sialic acid",{"date":230,"type":32},"2025-09-24",{"date":232,"type":21},"2025-09-25",{"date":234,"type":21},"2026-11-10",{"name":236,"class":75},"Xiaolong Li",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":245,"sex":16,"minAge":246,"maxAge":18,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":111},"100502783","safety-and-effectiveness-evaluation-of-the-colo-bt-as-an-alternative-treatment-to-the-ileostomy-100502783","NCT05826743","Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy","Safety and Effectiveness Evaluations of the COLO-BT™ (Colorectal Balloon Tube) as an Alternative Treatment to the Temporary Ileostomy Following Proctectomy","COLO-BT","Inclusion Criteria:\n\nThe patient must meet all study Inclusion Criteria as outlined below:\n\n* Adult males or females, 19-80 years of age, with signed informed consent\n\n  * Subject whose anastomosis is expected to be located above 4cm from the anus, and at or below 15cm from the anus. (4cm \\\u003C inclusion target ≤ 15cm from the anus).\n\n    ③ Patient must meet all other inclusion criteria to be eligible. While not required, if one or more of the following six risk factors for postoperative anastomotic leakage\\[6,7,8\\] is true, the patient will be considered a high-risk subject:\n\n    \\- Male\n\n    \\- Those with a body mass index of 30 or higher\n\n    \\- Current smoker\n\n    \\- Those who are on medication for diabetes\n\n    \\- Those with clinical stage III or higher malignant tumors\n\n    \\- Those who received chemo\u002Fradiation therapy before surgery\n\n    ④ Those who are willing and able to participate in this clinical study, provide Informed Consent, and are willing to comply with the study procedures and follow up evaluations\n\n    ⑤ Those who have willingness to undertake blood transfusion if required.\n\nExclusion Criteria:\n\nPatients meeting any of the following Exclusion Criteria will not be eligible to participate in the study:\n\n1. Women who are pregnant or breastfeeding\n2. Those who receive emergency surgery\n3. A person who is expected to need intensive medical care after the surgery due to a serious medical condition, with one or more of the following seven factors being true:\n\n   * Patients with abnormal bone marrow function (those with hemoglobin less than 7g\u002Fdl, leukocyte count less than 4000\u002Fmm3, or platelet count less than 100,000\u002Fmm3 even after preoperative corrections)\n   * Patients with severe liver damage or cirrhosis (those whose AST\u002FALT levels are more than three times the normal range or those diagnosed with cirrhosis)\n   * Those with abnormal renal function (those who are on hemodialysis or who have a blood creatinine level of 2.0mg\u002Fdl or more before the surgery)\n   * Those who have undergone cardiac or cerebrovascular stent procedure within the last 6 months\n   * Those who have been diagnosed with pulmonary tuberculosis within the last 6 months or are undergoing drug treatment for pulmonary tuberculosis\n   * Those who continuously administer steroids of 20mg\u002Fday or more within 30 days before the surgery\n   * Patients with ASA (American Society of Anesthesiologists) score of 3 are evaluated by the investigator who determines whether or not patients with ASA score of 3 should be enrolled from the patient safety standpoint. Patients with ASA score higher than 3 are excluded from this study.\n   * Patients who are required to undergo re-intervention to treat the anastomosis following intraoperative positive air leak test (However, patients who underwent complete reconstruction of the anastomosis in the presence of a positive air test, which therefore has made their risk of leak similar to those patients with a negative air leak test.)\n   * Patients who are immune suppressed\n   * Patients with severe diverticulosis\n   * Patients with other colonic wall abnormalities in the likely area of the Outer Balloon and BT BAND application who may be at increased risk for device perforation or migration.\n4. A person who has difficulty in mobility or is unable to communicate in general due to a psychiatric\u002Fneurologic disorder falling under one or more of the following:\n\n   * Those diagnosed with dementia or Alzheimer's disease.\n   * Those who have been diagnosed with schizophrenia or depression or are taking drugs due to this.\n   * A person who has been diagnosed with disability due to intellectual disability.\n5. Patients with intestinal perforation, abscess in the pelvis, or severe inflammation in the pelvis.\n6. Those who have a history of undergoing major surgeries (major bowel resection\u002Fmajor gastrectomy, major hepatectomy) through laparotomy and are likely to have serious adhesions that may affect this surgery.\n7. A patient who underwent a preoperative chemotherapy, but the anastomosis is expected to be located very close to the anus or in the anal canal, thus with a very high risk for complications of the anastomosis, or a patient whom the bowel function is expected to decrease significantly in the future.\n8. Patients who had pre-operative radiotherapy should be excluded.\n9. Patients with inflammatory bowel diseases such as ulcerative colitis, Crohn's disease, intestinal tuberculosis, or autoimmune diseases such as Bechet's disease.\n10. Those who do not consent in writing to the study.\n11. Experienced blood loss (\\>750 cc) within 6 weeks before randomization.\n12. Transfusion during surgery.\n13. Any new sign of ischemia within 6 weeks before randomization.\n14. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel all due to carcinomatosis within 6 weeks before randomization.\n15. Known hypersensitivity or allergy to any of the components required for the procedure.\n16. Exclusion criteria not specified above, but the patient is determined to be unsuitable for participation in this clinical study at the judgment of the researcher.",true,"19 Years",{"count":248,"type":21},256,[24],"The purpose of this study is to evaluate the Colorectal Balloon Tube (hereinafter referred to as COLO-BT™) device, a single use, temporary intraluminal bypass device, intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic)",[54,125,252,253,27],"Rectal\u002FAnal","Ileostomy - Stoma",[54,125,255,256,94],"Stoma","ileostomy","2025-06-12",{"date":259,"type":32},"2025-06-13",{"date":261,"type":32},"2023-12-04",{"date":263,"type":21},"2027-03-15",{"name":265,"class":266},"JSR Medical Co., Ltd.","INDUSTRY",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100556665","treatment-of-anastomotic-leakage-after-colon-cancer-resection-100556665","NCT06528054","TreatmENT of AnastomotiC LeakagE After COLON Cancer Resection","TreatmENT of AnastomotiC LeakagE After COLON Cancer Resection: the TENTACLE - Colon Study","TENTACLE-Colon","Inclusion criteria:\n\n* Aged 18 years or older;\n* Surgical resection for primary colon cancer (cT1-4b, N0-2, M0-1) with formation of a primary colonic anastomosis and with or without diverting stoma;\n* Postoperative AL defined as: \"any clinical, radiological or intraoperative signs of disrupted integrity of the anastomosis. This also includes suspected leaks with any degree of extraluminal air or fluid on CT, perianastomotic abscess, purulent peritonitis without clear anastomotic defect, or any other suspicious condition in which there is no ultimate macroscopic proof of disrupted anastomosis.\"\n* Regarding the type of colon cancer resection, the following patients will also fulfil the inclusion criteria: patients who underwent cytoreductive surgery (CRS) simultaneous with resection of the primary colon cancer with or without hyperthermic intraperitoneal chemotherapy (HIPEC), simultaneous ablations\u002Fresections of metastasis, multivisceral resection, emergency resection, patients diagnosed with perforated disease\u002Fperitumoral abscess or fistula, and acute obstructions.\n\nExclusion criteria:\n\n* Surgical resection for benign colon disease;\n* Recurrent colon cancer resection;\n* Any primary colon malignancy other than adenocarcinoma (e.g. neuroendocrine tumour, gastrointestinal stromal tumour);\n* Any clinical condition that does not fulfil the broad definition of AL as used in this study (e.g. only free air on CT that is considered to be compatible with an appropriate postoperative day in the absence of any other clinical signs related to a potential anastomotic leakage)",{"count":276,"type":21},2000,"This international multicentre retrospective cohort study aims to research anastomotic leakage after colon cancer resection and has two main objectives:\n\n1. To identify predictive factors associated with 90-day mortality and 90-day Clavien-Dindo grade 4-5 complications amongst patients who developed AL following colon cancer resection and to develop and validate a prediction model for predicting 90-day mortality as well as the co-primary composite endpoint Clavien-Dindo grade 4-5 complications.\n2. To explore and compare the effectiveness of various treatment strategies for AL following colon cancer resection, considering patient, tumour, resection and leakage characteristics.",[279,27,280,281],"Treatment","Resection","Colon Cancer","2024-07-29",{"date":284,"type":32},"2024-07-30",{"date":286,"type":21},"2024-10",{"date":288,"type":21},"2026-03",{"name":290,"class":75},"Radboud University Medical Center",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":40},"100554189","phase-2-prospective-phase-ii-study-on-continuous-circumferential-reinforcement-of-laparoscopic-rectal-anastomosis-to-prevent-complications-100554189","NCT06495853","Prospective Phase II Study on Continuous Circumferential Reinforcement of Laparoscopic Rectal Anastomosis to Prevent Complications","A Prospective Phase II Clinical Study on Continuous Circumferential Reinforcement of the Anastomotic Site With Laparoscopic Rectal Anastomosis to Prevent Complications.","Inclusion Criteria:\n\nHistological Confirmation:\n\nDiagnosed with rectal adenocarcinoma confirmed by histology.\n\nTumor Location:\n\nMRI confirms a mid to upper rectal tumor, with the lower margin of the tumor located 6-12 cm from the anal verge.\n\nPreoperative Staging:\n\nPreoperative MRI staging indicates the presence or absence of MRF positivity and\u002For EMVI positivity; the surgical team assesses the tumor as resectable with an estimated R0 resection.\n\nBowel Obstruction:\n\nNo signs of bowel obstruction.\n\nNeoadjuvant Chemoradiotherapy:\n\nFor patients who have received neoadjuvant chemoradiotherapy, complete radiotherapy and baseline imaging records must be available at this center.\n\nPrevious Treatments:\n\nSurgical History:\n\nNo previous colorectal surgery.\n\nBiological and Immunotherapy:\n\nNo prior treatment with biological drugs (e.g., monoclonal antibodies), immunotherapy (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-PD-L2 antibodies, or anti-CTLA-4), or other investigational drugs.\n\nEndocrine Therapy:\n\nNo restrictions on prior endocrine therapy.\n\nPatient Characteristics:\n\nAge:\n\nBetween 18 and 75 years old.\n\nPerformance Status:\n\nECOG performance status of 0-1 (see Appendix 3).\n\nLife Expectancy:\n\nGreater than 2 years.\n\nHematological Parameters:\n\nWBC \\> 3×10\\^9\u002FL; PLT \\> 80×10\\^9\u002FL; Hb \\> 90 g\u002FL.\n\nLiver Function:\n\nALT and AST less than 2 times the upper limit of normal; bilirubin less than 1.5 times the upper limit of normal.\n\nRenal Function:\n\nCreatinine less than 1.5 times the upper limit of normal or creatinine clearance (CCr) ≥ 60 ml\u002Fmin.\n\nExclusion Criteria:\n\nPatients meeting any of the following conditions will be excluded from the study:\n\nNeed for Multiorgan Resection:\n\nPatients requiring combined organ resection.\n\nPreventive or Permanent Stoma:\n\nPatients requiring preventive or permanent stoma.\n\nHartmann or Miles Procedures:\n\nPatients requiring Hartmann's procedure or Miles' surgery.\n\nCardiac Conditions:\n\nArrhythmias requiring antiarrhythmic treatment (excluding β-blockers or digoxin), symptomatic coronary artery disease, localized myocardial ischemia (myocardial infarction within the last 6 months), or congestive heart failure beyond NYHA Class II.\n\nUncontrolled Hypertension:\n\nSevere hypertension that is not well controlled by medication.\n\nInfectious Diseases:\n\nHistory of HIV infection or active chronic hepatitis B or C with high viral DNA copies.\n\nActive Tuberculosis (TB):\n\nSubjects with active pulmonary tuberculosis, currently undergoing anti-tuberculosis treatment, or having received anti-tuberculosis treatment within 1 year prior to screening.\n\nSevere Infections:\n\nOther active clinically severe infections (according to NCI-CTC version 5.0).\n\nEvidence of Distant Metastasis:\n\nPreoperative evidence of distant metastasis outside the pelvis.\n\nCachexia and Organ Failure:\n\nCachexia or decompensated organ function.\n\nRadiotherapy History:\n\nHistory of pelvic or abdominal radiotherapy.\n\nMultiple Primary Colorectal Cancers:\n\nPresence of multiple primary colorectal cancers.\n\nSeizure Disorders:\n\nPatients with seizures requiring treatment (e.g., steroids or antiepileptic therapy).\n\nHistory of Other Malignancies:\n\nHistory of other malignancies within the past 5 years, except for cured in situ cervical cancer or basal cell carcinoma of the skin.\n\nSubstance Abuse:\n\nSubstance abuse or medical, psychological, or social conditions that could interfere with the patient's participation in the study or the evaluation of study results.\n\nAllergies:\n\nKnown or suspected allergies to the investigational drug or any drug related to the study.\n\nUnstable Conditions:\n\nAny unstable condition or situation that might jeopardize patient safety and compliance.\n\nPregnancy or Lactation:\n\nWomen who are pregnant or breastfeeding, and women of childbearing potential not using adequate contraceptive measures.\n\nInformed Consent:\n\nRefusal to sign the informed consent form.",{"count":299,"type":21},208,[301],"PHASE2","Anastomotic leakage (AL) is one of the most severe complications following laparoscopic rectal cancer surgery. According to the International Study Group of Rectal Cancer (ISREC), AL is defined as a defect of intestinal wall integrity at the colorectal or coloanal anastomosis leading to a communication between the intra- and extraluminal compartments, including defects of the suture or staple lines of the neorectal reservoir. AL is classified into three grades based on clinical severity: Grade A, identified only radiologically without clinical symptoms; Grade B, presenting with localized or atypical peritonitis requiring antibiotics and local drainage but not surgery; and Grade C, causing severe peritonitis, systemic toxicity symptoms requiring urgent surgical intervention, and potentially leading to life-threatening situations.\n\nAL can prolong hospitalization, necessitate reoperation, delay chemotherapy, increase local recurrence rates, and adversely affect survival and quality of life. Emergency surgical management of AL often requires meticulous peritoneal lavage and ileostomy, aiming for subsequent anastomotic healing or future digestive tract reconstruction. However, some patients face significant challenges due to postoperative adhesions and persistent anastomotic defects despite prolonged lavage.\n\nIdentified risk factors for AL after rectal cancer surgery include male gender, advanced age, hypertension, diabetes, smoking, and advanced TNM staging (III-IV). Additionally, preoperative chemoradiotherapy-induced bowel edema and fibrosis, bowel obstruction, and long-term malnutrition resulting in hypoproteinemia are significant contributors. Mechanical reinforcement of anastomoses using sutures or absorbable barbed sutures has been shown to significantly reduce AL rates in previous studies.\n\nThis single-center prospective phase II clinical trial aims to evaluate the efficacy and safety of continuous circumferential reinforcement using absorbable barbed sutures in laparoscopic rectal anastomosis to prevent AL. We will compare the incidence of AL and other postoperative complications between patients undergoing reinforced anastomosis and a control group receiving standard laparoscopic rectal anastomosis.",[125,27,304],"Operation","2024-07-03",{"date":307,"type":32},"2024-07-11",{"date":309,"type":21},"2024-07-20",{"date":311,"type":21},"2025-11-01",{"name":313,"class":75},"ZHI-ZHONG PAN",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":245,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":40},"100519915","d2-versus-d3-dissection-in-laparoscopic-right-hemicolectomy-100519915","NCT06049758","D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy","D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy In Right Cancer Colon Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with right-side colon cancer (caecum, ascending, or hepatic flexure)\n* Diagnosed by CT entero-colonography\n* Diagnosed by colonoscopy\n* Diagnosed by biopsy.\n\nExclusion Criteria:\n\n* Emergency surgery (obstruction, perforation with generalized peritonitis),\n* Metastatic tumor diagnosed\n* ASA score of IV or higher\n* Need for more than one surgical procedure\n* Conversion to open surgery",{"count":322,"type":21},80,[24],"Evaluating the differences between D2 and D3 lymphadenectomy in laparoscopic right hemicolectomy in patients with right cancer colon post-operative outcome, intra-operative blood transfusion, post-operative ICU admission, anastomotic leakage, lymph node harvesting in the final specimen, and six months follow up and overall survival time after 5-years",[326,327,27,328,329,330],"Blood Loss","Intensive Care","Lymph Node Disease","Survival","Blood Transfusion","2023-09-19",{"date":333,"type":32},"2023-09-22",{"date":335,"type":21},"2024-01-02",{"date":337,"type":21},"2030-01-02",{"name":339,"class":39},"General Committee of Teaching Hospitals and Institutes, Egypt"]